Scarica l'app Stockscreener
37.32
0.21%
-0.08
Dopo l'orario di chiusura:
37.32
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$37.40
Aprire:
$37.635
Volume 24 ore:
10.16M
Relative Volume:
0.84
Capitalizzazione di mercato:
$164.83B
Reddito:
$50.91B
Utile/perdita netta:
$18.95B
Rapporto P/E:
8.7585
EPS:
4.261
Flusso di cassa netto:
$1.92B
1 W Prestazione:
-3.81%
1M Prestazione:
-20.21%
6M Prestazione:
+0.92%
1 anno Prestazione:
-36.47%
Intervallo 1D:
$37.17
$37.65
Intervallo di 1 settimana:
$37.17
$38.90
Portata 52W:
$35.12
$64.16
Novo Nordisk Adr Stock (NVO) Company Profile
Nome
Novo Nordisk Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare NVO vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
37.32 | 171.37B | 50.91B | 18.95B | 1.92B | 4.261 |
LLY
Lilly Eli Co
|
1,142.85 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.03 | 623.34B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
262.82 | 459.33B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.30 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.00 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Iniziato | Wolfe Research | Peer Perform |
| 2026-03-18 | Iniziato | Bernstein | Outperform |
| 2026-03-10 | Downgrade | TD Cowen | Buy → Hold |
| 2026-03-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2026-03-02 | Downgrade | Goldman | Buy → Neutral |
| 2026-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2026-02-24 | Downgrade | Kepler | Buy → Hold |
| 2026-02-23 | Downgrade | Deutsche Bank | Buy → Hold |
| 2026-02-12 | Aggiornamento | Jefferies | Underperform → Hold |
| 2026-01-27 | Iniziato | Citigroup | Neutral |
| 2025-12-08 | Downgrade | Argus | Buy → Hold |
| 2025-10-27 | Ripresa | Jefferies | Underperform |
| 2025-10-01 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-29 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-09-16 | Aggiornamento | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Downgrade | UBS | Buy → Neutral |
| 2025-07-31 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-30 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Aggiornamento | Kepler | Hold → Buy |
| 2025-03-03 | Downgrade | Stifel | Buy → Hold |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Neutral |
| 2023-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Iniziato | Argus | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2022-07-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Downgrade | UBS | Neutral → Sell |
| 2022-06-27 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-04-25 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2022-04-12 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Downgrade | Liberum | Hold → Sell |
| 2021-12-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-07-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-05-11 | Downgrade | UBS | Buy → Neutral |
| 2020-05-04 | Iniziato | Cowen | Market Perform |
| 2020-03-16 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-11-18 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-30 | Downgrade | Jefferies | Hold → Underperform |
| 2019-06-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Iniziato | Exane BNP Paribas | Outperform |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2017-12-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
Mostra tutto
Novo Nordisk Adr Borsa (NVO) Ultime notizie
Eli Lilly vs. Novo Nordisk: valuation gap and pairs trade framework - Investing.com
Novo's Wegovy Pill Shows Weight Loss After Switching From Injections - Zacks Investment Research
Novo Nordisk A/S Sponsored ADR Class B Earnings and Revenue – HAN:NOVA - TradingView
NOVA Forecast — Price Target — Prediction for 2027 - TradingView
ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView
Novo Nordisk A/Sshare repurchase programme - Finansavisen
Novo Nordisk Weighs Direct NYSE Listing as U.S. Investors Push for Closer Access - finance.biggo.com
Novo Nordisk Is Open To A Direct NYSE Listing - Finimize
Novo Nordisk CEO opens the door to major move for U.S. investors - thestreet.com
Novo Nordisk open to direct NYSE listing, CEO s... - Pluang
Novo CEO Considering Direct Shares Listing: Report - Pharmaceutical Executive
Novo Nordisk Open to Direct NYSE Listing, CEO Tells FT - Global Banking & Finance Review
Key facts: NOVO_B: DKK150bn Plan; Mixed CagriSema, Oral Wegovy Sales - tradingview.com
Novo wants to change how Wall Street owns its stock: why now - Invezz
Novo Nordisk open to New York listing upgrade, CEO Doustdar tells FT By Reuters - Investing.com
Novo Nordisk stock falls sharply as Capital Markets Day disappoints investors - AD HOC NEWS
Novo's Cardiometabolic Business Is Concentrated in Semaglutide, but the Pipeline Is Growing - Morningstar
European ADRs Started The Week Higher In US Trading - Finimize
Novo Nordisk Stock Slides 8% as $23 Billion Pipeline Goal Leaves a 2032 Gap - TechStock²
Novo Nordisk ADR shares tumble over 7% on Wall Street as long-term plan fails to impress investors - upstox.com
Novo-Nordisk stock heads into the open after a 0.1 percent gain - AD HOC NEWS
Novo Nordisk stock reacts to CHMP backing for FREHEMGO and Novo rebranding - AD HOC NEWS
Novo Nordisk stock gains as analysts see up to 50 percent upside - AD HOC NEWS
Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A - Finansavisen
Novo Nordisk stock heads into the open after a 2.1% slide - AD HOC NEWS
Novo Nordisk stock falls as rebrand to Novo meets cautious analyst response - AD HOC NEWS
NVO Stock Quote Price and Forecast - CNN
Novo Nordisk stock extends buyback as trial updates and obesity growth shape outlook - ad-hoc-news.de
Novo Nordisk (NYSE: NVO) has bought back 32M shares, with its 12‑month repurchase plan still running - Stock Titan
Novo Nordisk stock heads into the open after a 2.3% slide - AD HOC NEWS
Novo Nordisk stock falls as heart drug trials are halted despite pediatric obesity win - AD HOC NEWS
Eli Lilly vs. Novo Nordisk: One Has 39% Upside. I'm Picking the Other. - Barchart.com
Novo Nordisk trial shows semaglutide helped 40% of children - Investing.com
Weekly Recap: Oral Wegovy launch in Germany and DKK8.7077bn buyback - TradingView
Novo Nordisk stock dips as Wegovy pill launch in Germany reshapes obesity market - AD HOC NEWS
European ADRs Push Higher In Wednesday Session Led By ING, IHG, And Novo Nordisk - foreignpolicyjournal.com
From hunger to obesity: Developing world faces growing threat to child health By Reuters - Investing.com
European ADRs Inched Higher As Healthcare Led Gains - Finimize
Novo Nordisk stock reacts to downgrade as oral obesity push advances in Asia - ad-hoc-news.de
European ADRs Slipped In US Trading Late Thursday Morning - Finimize
Novo Nordisk Adr Azioni (NVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):